Anogen-Yes Biotech Laboratories LTD.

Check out how Anogen’s Multiplex Human Cytokine ELISA Kit (M1/M2/MDSC Cytokines) played a crucial role in a study published in Oncotarget on non-functional pituitary adenomas (NFPAs). 🧠 The study revealed how tumor-associated macrophages (TAMs) impact tumor progression—M1 macrophages act against tumors, while M2 macrophages promote tumor growth. The findings will aid the development of immunomodulatory therapies for NFPAs. Anogen proudly supports cancer research with top-quality antibodies and ELISA kits. Visit www.anogen.ca to learn more! #Anogen #CancerResearch #Immunotherapy #Anogen #ELISAKits #TumorMicroenvironment

Researchers at the University of Texas have developed a promising new nasal spray treatment that could help combat dementia. This experimental spray delivers antibodies that target and reduce the harmful "tau" protein buildup in the brain, a major contributor to Alzheimer's and other neurodegenerative diseases. In trials with mice, just a single dose reduced tau accumulation and improved cognitive function! https://lnkd.in/eWcbuaAg #Anogen #DementiaResearch #Alzheimers #NeurodegenerativeDiseases #Breakthroughs #Healthcare #Innovation

Researchers at Brigham and Women's Hospital have discovered an exciting potential treatment for COVID-19 and other diseases using Foralumab, a nasal monoclonal antibody. Unlike previous treatments, this drug doesn't just target the virus but tackles inflammation, a major cause of many illnesses, including multiple sclerosis (MS). In early trials, patients with COVID-19 who received Foralumab experienced reduced lung inflammation. Intriguingly, it also showed similar effects in MS patients, suggesting that it could be used to treat a variety of inflammatory conditions. Read the full article: https://lnkd.in/eMnPM9BM #Anogen #COVID19 #MS #MonoclonalAntibodies #Immunotherapy #Foralumab #HealthcareInnovation #InflammationResearch

A new study offers promising insights into improving survival rates for pancreatic cancer patients. Researchers focused on two key elements: 1️⃣ HLA Class I Expression: If this immune marker is high, it signals that the body is better equipped to fight the cancer. 2️⃣ B7-H3 Expression: This molecule allows cancer to escape immune detection. High levels of B7-H3 are linked to poorer survival outcomes. 🔬 By targeting B7-H3 with advanced therapies like CAR-T cells, there’s hope for a breakthrough in pancreatic cancer treatment. This approach could shift the paradigm towards personalized immunotherapy, potentially improving survival rates in the future. Read the full article: https://lnkd.in/efZybQnN #PancreaticCancer #Immunotherapy #CancerResearch #PrecisionMedicine #CAR-T #biotechnology #Anogen

Researchers from the University of Texas Medical Branch have developed an innovative nasal spray targeting tau proteins, a major culprit in Alzheimer’s. Unlike current treatments focused on amyloid, this spray breaks through the blood-brain barrier to eliminate toxic tau buildup, improving memory in mouse models. While human trials are still needed, this non-invasive therapy offers new hope for battling neurodegenerative diseases like Alzheimer’s. Stay tuned for more updates! Read the full article: https://lnkd.in/eMwsCvm7 #AlzheimersResearch #NasalSprayTherapy #NeurodegenerativeDiseases #TauProtein #brainhealth #Anogen

Tau protein accumulation is a hallmark of Alzheimer's and other neurodegenerative diseases, leading to cognitive decline. A new study shows promise for a novel intranasal tau immunotherapy, using the TTCM2 antibody to target and clear pathological tau. This treatment improved cognitive function in tauopathy mice, potentially paving the way for breakthroughs in Alzheimer's therapies by reversing brain pathology and restoring memory function. Researchers hope this could translate into new treatments for patients, offering hope for reversing or delaying severe dementia symptoms. Read the full article: https://lnkd.in/egmB7kDz #AlzheimersResearch #Neurodegeneration #TauImmunotherapy #CognitiveHealth #Anogen

Researchers have developed a nasal immunotherapy that clears harmful tau aggregates from the brain, improving cognitive functions in aged mice with tauopathies like Alzheimer’s disease. Using a conformation-specific antibody, this therapy targets intracellular tau proteins, a challenge in current treatments, and shows promise in treating other neurodegenerative diseases. Read the full article: https://lnkd.in/efEZ-D-D #AlzheimersResearch #Neuroscience #MedicalInnovation #BrainHealth #TauImmunotherapy #Breakthrough #Anogen

Scientists at Brigham and Women's Hospital have developed a groundbreaking intranasal vaccine aimed at tackling Alzheimer’s disease. This innovative treatment, which has shown promising results in early trials, utilizes Protollin to stimulate the body’s immune system to clear beta-amyloid plaques from the brain—one of the hallmarks of Alzheimer’s. Led by Dr. Howard L. Weiner, the study marks a major milestone as it enters the first phase of human trials, targeting participants with early, symptomatic Alzheimer's disease. The approach is not only novel but also non-invasive, offering a potential new avenue for treating neurodegenerative diseases. This could be the future of Alzheimer’s treatment and prevention—imagine a simple nasal spray that not only treats but could potentially prevent the disease in at-risk individuals! 🧬 Read the full article: https://lnkd.in/gnU4Aqaa #AlzheimersResearch #MedicalInnovation #Neurology #HealthcareBreakthrough #Protollin #BrainHealth #Anogen

Scientists in the U.S. have developed a groundbreaking nasal spray that targets the tau protein, a key player in Alzheimer’s disease. While most treatments focus on clearing amyloid plaques, this innovative approach tackles the harmful tau “tangles” inside neurons, which contribute to memory loss and cognitive decline. In studies with aged mice, this nasal spray significantly reduced tau buildup and even improved memory and cognitive functions. Although still in the early stages and yet to be tested in humans, this non-invasive method offers promising potential for treating Alzheimer’s and other neurodegenerative diseases. Read the full article here: https://lnkd.in/gPG2rQ2W. #AlzheimersResearch #Neuroscience #InnovativeTherapies #BrainHealth #MedicalBreakthrough #Anogen

Researchers at the University of Texas Medical Branch have unveiled a groundbreaking advancement in the fight against neurodegenerative diseases like Alzheimer’s and dementia! 🌟🧪 Dr. Rakez Kayed and his team have developed a special antibody, TTCM2, designed to selectively target toxic tau buildup. Packaged in particles for enhanced delivery, this nasal spray method bypasses the blood-brain barrier, ensuring rapid and effective treatment. 🚀🧠 By harnessing the power of TRIM21, an intracellular receptor, this method not only enhances the delivery of therapeutic antibodies but also boosts their efficacy in clearing tau aggregates. This could revolutionize treatment strategies for Alzheimer’s and related tauopathies, offering new hope for millions suffering from these debilitating conditions. 🌍💪 UTMB’s next steps involve advancing this research with preclinical trials and exploring TTCM2-ms in human studies. With support from NIH, Alzheimer’s Association, and UTMB Claude D. Pepper OAIC Pilot grant, this research is paving the way for future treatment options. 🧬🔬 Stay tuned for more updates on this promising development and its potential impact on neurodegenerative disease treatments! 💖👩🔬👨🔬 Read the full article: https://lnkd.in/gi2KtXAY #NeurodegenerativeDisease #AlzheimersResearch #MedicalBreakthrough #NasalSprayInnovation #TauTherapy #ScienceNews #UTMB #CognitiveHealth #FutureOfMedicine #Anogen